Mesothelin expression is associated with poor outcomes in breast cancer

Breast Cancer Research and Treatment

Volumn 147, Issue 3, 2014, Pages 675-684

  Li, Yun R ^a,b   Xian, Rena R ^a,e   Ziober, Amy ^a   Conejo Garcia, Jose ^c   Perales Puchalt, Alfredo ^c   June, Carl H ^a,d   Zhang, Paul J ^a   Tchou, Julia ^a,d,f  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

^c WISTAR INSTITUTE   (United States)

^d UNIVERSITY OF PENNSYLVANIA   (United States)

^e JOHNS HOPKINS UNIVERSITY   (United States)

^f Perelman Center for Advanced Medicine   (United States)

Author keywords

Basal tumor subtype; Breast cancer outcome; Breast cancer subtype; Mesothelin; Targeted therapy; Triple negative breast cancer (TNBC); Tumor marker

Indexed keywords

MESOTHELIN; RNA; TRANSCRIPTOME; GLYCOSYLPHOSPHATIDYLINOSITOL ANCHORED PROTEIN; TUMOR MARKER;

ADULT; ARTICLE; AXILLARY LYMPH NODE; CANCER STAGING; CANCER TISSUE; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE SPECIFIC SURVIVAL; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; OUTCOME ASSESSMENT; PROTEIN EXPRESSION; TRIPLE NEGATIVE BREAST CANCER; TUMOR VOLUME; VALIDATION STUDY; AGED; BREAST TUMOR; CLINICAL TRIAL; DISEASE FREE SURVIVAL; FEMALE; GENE EXPRESSION REGULATION; GENETICS; KAPLAN MEIER METHOD; LYMPH NODE; METABOLISM; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; PATHOLOGY; PROGNOSIS;

ADULT; AGED; BIOMARKERS, TUMOR; BREAST NEOPLASMS; COHORT STUDIES; DISEASE-FREE SURVIVAL; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GPI-LINKED PROTEINS; HUMANS; KAPLAN-MEIER ESTIMATE; LYMPH NODES; MIDDLE AGED; PROGNOSIS; TRIPLE NEGATIVE BREAST NEOPLASMS;

EID: 84918533722     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-014-3077-5     Document Type: Article

References (20)

1. Chang K, Pai LH, Pass H et al (1992) Monoclonal antibody K1 reacts with epithelial mesothelioma but not with lung adenocarcinoma. Am J Surg Pathol 16:259–268
2. Chang K, Pastan I (1996) Molecular cloning of mesothelin, a differentiation antigen present on mesothelium, mesotheliomas, and ovarian cancers. Proc Natl Acad Sci U S A 93:136–140
3. Kojima T, Oh-eda M, Hattori K et al (1995) Molecular cloning and expression of megakaryocyte potentiating factor cDNA. J Biol Chem 270:21984–21990
4. Bera TK, Pastan I (2000) Mesothelin is not required for normal mouse development or reproduction. Mol Cell Biol 20:2902–2906
5. Rump A, Morikawa Y, Tanaka M et al (2004) Binding of ovarian cancer antigen CA125/MUC16 to mesothelin mediates cell adhesion. J Biol Chem 279:9190–9198
6. Argani P, Iacobuzio-Donahue C, Ryu B et al (2001) Mesothelin is overexpressed in the vast majority of ductal adenocarcinomas of the pancreas: identification of a new pancreatic cancer marker by serial analysis of gene expression (SAGE). Clin Cancer Res 7:3862–3868
7. Swierczynski SL, Maitra A, Abraham SC et al (2004) Analysis of novel tumor markers in pancreatic and biliary carcinomas using tissue microarrays. Hum Pathol 35:357–366
8. Ordóñez NG (2003) Value of mesothelin immunostaining in the diagnosis of mesothelioma. Mod Pathol 16:192–197. doi:10.1097/01.MP.0000056981.16578.C3
9. Wu JM, Fackler MJ, Halushka MK et al (2008) Heterogeneity of breast cancer metastases: comparison of therapeutic target expression and promoter methylation between primary tumors and their multifocal metastases. Clin Cancer Res 14:1938–1946. doi:10.1158/1078-0432.CCR-07-4082
10. Tchou J, Wang LC, Selven B et al (2012) Mesothelin, a novel immunotherapy target for triple negative breast cancer. Breast Cancer Res Treat 133:799–804
11. Kelly RJ, Sharon E, Pastan I, Hassan R (2012) Mesothelin-targeted agents in clinical trials and in preclinical development. Mol Cancer Ther 11:517–525
12. Kawamata F, Kamachi H, Einama T et al (2012) Intracellular localization of mesothelin predicts patient prognosis of extrahepatic bile duct cancer. Int J Oncol 41:2109–2118. doi:10.3892/ijo.2012.1662
13. Einama T, Homma S, Kamachi H et al (2012) Luminal membrane expression of mesothelin is a prominent poor prognostic factor for gastric cancer. Br J Cancer 107:137–142
14. Yen MJ, Hsu CY, Mao TL et al (2006) Diffuse mesothelin expression correlates with prolonged patient survival in ovarian serous carcinoma. Clin Cancer Res 12:827–831
15. Wang L, Niu Z, Zhang L et al (2012) Clinicopathological significance of mesothelin expression in invasive breast cancer. J Int Med Res 40:909–916
16. Parinyanitikul N, Blumenschein GR, Wu Y et al (2013) Mesothelin expression and survival outcomes in triple receptor negative breast cancer. Clin Breast Cancer 13:378–384
17. Kandoth C, McLellan MD, Vandin F et al (2013) Mutational landscape and significance across 12 major cancer types. Nature 502:333–339
18. McShane LM, Altman DG, Sauerbrei W et al (2005) Reporting recommendations for tumor marker prognostic studies (REMARK). J Natl Cancer Inst 97:1180–1184
19. Li B, Dewey CN (2011) RSEM: accurate transcript quantification from RNA-Seq data with or without a reference genome. BMC Bioinformatics 12:323
20. Robinson MD, McCarthy DJ, Smyth GK (2010) edgeR: a bioconductor package for differential expression analysis of digital gene expression data. Bioinformatics 26:139–140